摘要
目的探讨盐酸替扎尼定联合坦度螺酮治疗纤维肌痛综合征(FS)的有效性及安全性。方法 46例符合美国风湿病学院(ACR)FS标准的患者随机分为两组,A组(盐酸替扎尼定组)20例,B组(盐酸替扎尼定联合坦度螺酮组)26例。经12周治疗后,比较两组患者目测标尺法(VAS)评分、日常生活能力(ADL)评分、纤维肌痛影响问卷调查(FIQ)评分、Hamilton焦虑量表(HAMA)评分、Hamilton抑郁量表(HAMD)评分。结果经12周治疗后,两组患者的VAS评分、HAMA评分、HAMD评分、FIQ评分均较治疗前有显著降低,ADL评分较治疗前升高明显(P<0.05)。两组患者治疗前后的VAS评分、HAMA评分、HAMD评分、ADL评分、FIQ评分差值比较有显著性差异(P<0.05)。结论盐酸替扎尼定联合坦度螺酮治疗纤维肌痛综合征能明显提高临床疗效,无严重不良反应发生,安全性好。
Objective To evaluate the efficacy and safety of tizanidine hydrochloride combined with tandospirone in fi-bromyalgia symdrome(FS). Methods 46 cases up to the stardard of the American College of rheumatology (CAR) FS patients were randomly divided into two groups, group A for tizanidine hydrochloride, group B for tizanidine hydrochloride combined with tandospirone. After 12 weeks of treatment,compared VAS score,FIQ score,HAMA score and HAMD score of two groups. Results VAS score,ADL score, FIQ score,HAMA score and HAMD score of two groups after 12 weeks of treatment were lower than that before treatment, ADL score was higher than that before treatment, the difference was statistically significant (P<0.05). Compared the difference value of VAS score, ADL score, HAMA score, HAMD score, FIQ score of two groups before and after the treatment, the differences were statistically significant (P<0.05). Conclusion Tizanidine hydrochloride com-bined with tandospirone in the treatment of fibromyalgia syndrome can significantly improve the clinical efficacy. There is no se-rious adverse reaction.
出处
《中国现代医药杂志》
2016年第5期32-35,共4页
Modern Medicine Journal of China
